What’s new with DNA and RNA?
Eukaryotic gene expression is regulated at multiple layers. This session will cover emerging new mechanisms of gene expression regulation, centered around DNA and RNA. We will hear updates on regulation at the nucleosome structure and chromatin conformation level, how noncoding RNAs could impact transcription, and RNA modifications in post-transcriptional gene expression regulation. This session also will introduce diverse modern imaging technologies to visualize transcription activity and spatial transcriptome.
Keywords: chromatin structure, noncoding RNA, RNA modifications, super-resolution imaging, spatial transcriptome
Who should attend: students, postdocs and anyone interested in gene expression regulation, nucleosome structure and chromatin conformation, noncoding RNA and RNA modifications, super-resolution imaging and spatial transcriptome
Theme song: "The DNA Song" by Jam Campus (parody of "Trap Queen" by Fetty Wap)
This session is powered by nucleic acids.
Talks
- Cracking the nucleus: Finding order in chaos — Clodagh O'Shea, Salk Institute
- EM structures of nucleosomes with chaperones — Karolin Luger, University of Colorado Boulder
- Structural mechanism of human telomerase holoenzyme — Kelly Nguyen, Medical Research Council Laboratory of Molecular Biology
- Studying DNA-related processes on DNA curtains — Ilya Finkelstein, University of Texas at Austin
- m6A in the action of regulating the regulators — Kathy (Fange) Liu, University of Pennsylvania
- Jeannie Lee, Massachusetts General Hospital
- RNA methylation multitasking on chromatin — Blerta Xhemalce, University of Texas at Austin
- RNA methylation in gene expression regulation — Chuan He, University of Pennsylvania
- Visualizing RNA in life cells — Timothy Stasevich, Colorado State University
- Visualizing the dynamic genome during development, Alistair Boettiger, Stanford University
- 3D in situ RNA sequencing — Xiao Wang, Broad Institute and Massachusetts Institute of Technology
- Engineering the repetitive 3D genome in human disease— Jennifer Phillips–Cremins, University of Pennsylvania
Learn more
Check out all ten thematic symposia planned for the 2022 ASBMB annual meeting:
- Diversity, equity and inclusion
- Protein machines and disorder
- Signaling
- Quality control in organelles
- Metabolism
- Enzymology
- RNA/DNA
- Membranes/lipids
- Glycobiology
- Education and professional development
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreFeatured jobs
from the ASBMB career center
Get the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Differences in pili structure modulate bacterial behavior
Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.
Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.
Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.
Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.
The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.
Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.